CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive specialty pharmacy partner for ENCELTOtm (revakinagene taroretcel-lwey), an ...

Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

Gage Poole, his two parents, Gaston and Kieryanne Poole, and three siblings live in Nicholasville, Kentucky. For his 10th ...

Ataxia Treatment Market, trends, and advancements in neurological disorder treatments. Discover growth drivers, key players, and forecasts up to 2035 ...

Usually, you do not need to worry about a nosebleed (epistaxis). Most nosebleeds stop after a few minutes with at-home care, like pinching your nose and leaning forward. A nosebleed can be a serious ...